top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


A Gene Therapy for Dravet Syndrome Cuts Seizures and Supports Development
At ASGCT 2026, Encoded Therapeutics shared one-year data for ETX101, an AAV9 gene regulation therapy for Dravet syndrome that cut seizures by about 76% at the top dose. A pivotal study is now underway.
May 12


Grace Science's GS-100 Earns RMAT Designation for NGLY1 Deficiency
Grace Science's GS-100, an AAV9 gene therapy for NGLY1 deficiency, earned FDA RMAT designation after treated children showed gains in motor and cognitive skills. Here's how it works and why it matters.
Apr 13
bottom of page


